Session	Start-ups/SMEs looking for Finance: Pre-seed/Angel/Seed
Title	Cell-free biocatalysis for affordable bioactive sugars in nutrition and beyond
Company	eversyn GmbH
Speaker	Thomas Rexer
TRL	TRL 4 - 7
Keywords feedstock (max 2)	Abundant sugars
Keywords technology (max 2)	Cell-free biocatalysis
Keywords End-Product (max 2)	Nucleotide sugars

Abstract:

Complex sugars (glycans) determine the function of many high-value bio-based products, from human milk oligosaccharides and functional food ingredients to personal care and health applications. Producing them precisely and affordably remains a key bottleneck: their activated building blocks, nucleotide sugars, cost up to €1-2M per kg today. eversyn, a Max Planck spin-off from Magdeburg, has developed cell-free, GMO-free multi-enzyme cascades that convert abundant, low-cost sugars into nucleotide sugars with up to 95% yield, enabling precise and scalable glycosylation at a fraction of current costs. In a proof of concept with an international nutrition company, we turned a glycan into a manufacturable infant-nutrition ingredient: sialylated glycans increased 6-fold, total sialylation reached more than 90%, and we delivered purified, sialylated ingredient. The same platform serves customers in food, health and life sciences. With 4 granted patents (+1 pending), 40+ paying customers in 20+ countries and €3.3M in seed and grant funding, eversyn is now scaling up to industrial volumes. We are looking for investors and industrial partners to bring affordable, biobased bioactive sugars to the European bioeconomy.